Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2006

01-08-2006 | Brief Report

In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients

Authors: A. Cometta, O. Marchetti, T. Calandra, J. Bille, W. V. Kern, S. Zinner, Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG)

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2006

Login to get access

Excerpt

The use of fluoroquinolones has increased in neutropenic cancer patients over the past two decades. With respect to empiric treatment of fever in neutropenic patients, the poor activity of older quinolones against gram-positive cocci prompted physicians to add specific anti-gram-positive agents to provide better activity against streptococci, which are frequently isolated from these patients. The efficacy and safety of oral antibiotic regimens that include fluoroquinolones for the treatment of low-risk febrile neutropenic patients have been documented in two large studies [1, 2]. The widespread use of fluoroquinolones as prophylactic agents in cancer patients has been associated with the occurrence of resistance in E. coli and coagulase-negative staphylococci, organisms which are most often responsible for bacteremia in these patients [3]. …
Literature
1.
Kern WV, Cometta A, de Bock R, Langenaeken J, Paesmans M, Gaya H, for the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312–318PubMedCrossRef
2.
Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311PubMedCrossRef
3.
Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240–1241PubMedCrossRef
4.
Keating GM, Scott LJ (2004) Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 64:2347–2377PubMedCrossRef
5.
Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken J, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP, for The EORTC International Antimicrobial Therapy Cooperative Group (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108–1115PubMed
6.
Cometta A, Kern WV, de Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam B, Gaya H, Padmos A, Klastersky J, Zinner SH, Glauser M, Calandra T, Viscoli C, for the International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer (2003) Vancomycin versus placebo for persistent fever in neutropenic cancer patients given piperacillin/tazobactam monotherapy: an EORTC-IATG multicenter, double-blind, placebo-controlled trial. Clin Infect Dis 37:382–389PubMedCrossRef
7.
Murray PQ (2003) Manual of clinical microbiology. 8th edition. ASM, Washington DC. pp 185–207
8.
Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. CLSI document, vol 25(1):M100–S15
9.
Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P (2003) In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 9:997–1005PubMedCrossRef
10.
Rolston KV, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH (2003) In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis 47:441–449PubMedCrossRef
11.
Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39 (Suppl 1):25–31CrossRef
Metadata
Title
In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients
Authors
A. Cometta
O. Marchetti
T. Calandra
J. Bille
W. V. Kern
S. Zinner
Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG)
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-006-0175-2

Other articles of this Issue 8/2006

European Journal of Clinical Microbiology & Infectious Diseases 8/2006 Go to the issue

Article

Elevated procalcitonin as a diagnostic marker in meningococcal disease

Concise Article

Hemolytic uremic syndrome in an infant following Bordetella pertussis infection

Article

Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock

Brief Report

Serological evidence of human infection with rickettsial strain Bar29 in Catalonia, northeastern Spain

Article

Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies

Brief Report

Wild boars as possible source of hemorrhagic leptospirosis in Berlin, Germany
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits